JERUSALEM, Israel, Sept. 16,
2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
(Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical
company specializing in inflammation and immunology (I&I)
biological products and providing CDMO services through its Scinai
Bioservices unit, today announced that it will be hosting a
scientific webinar on Wednesday, September
18, 2024, at 11 AM EDT / 18:00
Israel time. The webinar will
address the unmet needs in treating mild to moderate plaque
psoriasis and explore intralesional injections of Scinai's novel
anti-IL-17A/F VHH antibody as a promising solution. Additional
topics will include an introduction to single domain VHH
antibodies, Scinai's pipeline and a review of the biological drug
development journey towards marketing authorization.
The virtual panel discussion will feature:
- Mr. Amir Reichman, CEO of Scinai, who will serve as
moderator;
- Dr. Tamar Ben Yedidia,
Chief Scientific Officer at Scinai;
- Prof. Michael Schoen,
Director of Dermatology and Venerology at the University Medical
Center Göttingen, Germany (UMG)
and an independent medical consultant of Scinai; and
- Prof. Matthias
Dobbelstein, Max Planck Institute Fellow and Department
Head at UMG and a member of Scinai's Scientific Advisory
Board.
The webinar will be broadcast via Zoom. Interested participants
can register using the following LINK.
The discussion will provide an in-depth exploration of the
plaque psoriasis landscape, current treatment options, existing
unmet needs, and the potential of intralesional injections of
anti-IL-17A/F single domain VHH antibodies to offer a superior
treatment for those affected. Topics will include:
- An overview of the plaque psoriasis landscape, the current
treatment options and the unmet need;
- Understanding what single domain VHH antibodies are and
how they are made;
- Comparing the advantages and limitations of VHH antibodies to
conventional monoclonal antibodies;
- The various stages of biologic drug development and the steps
taken by Scinai in developing its novel anti-IL-17 VHH antibody for
psoriasis treatment;
- The target product profile of Scinai's leading drug intended
for intralesional application via a pen injector and a review of
Scinai's pre-clinical results and plans for clinical trials;
and
- Insights into Scinai's extensive pipeline of VHH antibodies
developed in collaboration with the Max Planck Institute in
Göttingen and UMG.
Participants will also have the opportunity to submit questions
and receive answers during a Q&A session at the end of the
webinar.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(NanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical cGMP manufacturing, and
pre-clinical and clinical trial design and execution services for
early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, are forward-looking statements.
Examples of such statements include, but are not limited to,
Scinai's novel anti-IL-17A/F VHH antibody being a potential
solution to treat mild to moderate plaque psoriasis. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and uncertainties include,
but are not limited to; the risk that the Company will otherwise be
unable to remain compliant with the continued listing requirements
of Nasdaq; lower than anticipated revenues of Scinai's CDMO
business in 2024 and thereafter; failure to sign agreements with
other potential clients of the CDMO business; a delay in the
commencement and results of pre-clinical and clinical studies; the
risk of delay in, Scinai's inability to conduct, or the
unsuccessful results of, its research and development activities,
including the contemplated in-vivo studies and a clinical trial;
the risk that Scinai will not be successful in expanding its CDMO
business or in-license other NanoAbs; the risk that Scinai may not
be able to secure additional capital on attractive terms, if at
all; the risk that the therapeutic and commercial potential of
NanoAbs will not be met or that Scinai will not be successful in
bringing the NanoAbs towards commercialization; the risk of a delay
in the preclinical and clinical trials data for NanoAbs, if any;
the risk that Scinai's business strategy may not be successful;
Scinai's ability to acquire rights to additional product
opportunities; Scinai's ability to enter into collaborations on
terms acceptable to Scinai or at all; timing of receipt of
regulatory approval of Scinai's manufacturing facility in
Jerusalem, if at all or when
required; the risk that the manufacturing facility will not be able
to be used for a wide variety of applications and other vaccine and
treatment technologies; and the risk that drug development involves
a lengthy and expensive process with uncertain outcomes. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the
Company's Annual Report on Form 20-F filed with the Securities and
Exchange Commission ("SEC") on May 15,
2024, and the Company's subsequent filings with the SEC.
Scinai undertakes no obligation to revise or update any
forward-looking statement for any reason.
Photo:
https://mma.prnewswire.com/media/2506153/Scinai_Immunotherapeutics.jpg
Logo: https://mma.prnewswire.com/media/2310190/4912970/Scinai_Immunotherapeutics_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scinai-to-host-online-expert-panel-on-plaque-psoriasis-treatment-and-intralesional-injections-of-anti-il-17af-vhh-antibodies-302248933.html
SOURCE Scinai Immunotherapeutics Ltd.